Drug induced QT prolongation

Cardiology Journal

Volumn 14, Issue 6, 2007, Pages 523-533

  Zareba, Wojciech ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Drug induced QT prolongation; Long QT syndrome; QT interval; Torsade de pointes

Indexed keywords

AMANTADINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ASTEMIZOLE; CALCIUM CHANNEL BLOCKING AGENT; CHLOROQUINE; CISAPRIDE; CLARITHROMYCIN; DIURETIC AGENT; ERYTHROMYCIN; GASTROINTESTINAL AGENT; GREPAFLOXACIN; HORMONE; KETOCONAZOLE; MACROLIDE; MOXIFLOXACIN; NEUROLEPTIC AGENT; PROKINETIC AGENT; SERTINDOLE; SOTALOL; SPARFLOXACIN; TAMOXIFEN; TERFENADINE; UNINDEXED DRUG; VERAPAMIL;

CHANNELOPATHY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; GENE MUTATION; GENETIC PREDISPOSITION; HEART ARRHYTHMIA; HEART PROARRHYTHMIA; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; NONHUMAN; PATHOGENESIS; POSTMARKETING SURVEILLANCE; QT INTERVAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH; T WAVE; TORSADE DES POINTES;

EID: 39549121040     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Moss AJ, Schwartz PJ, Crampton RS et al. The long QT syndrome: Prospective longitudinal study of 328 families. Circulation, 1991; 84: 1136-1144.
2. Moss AJ. The QT interval and torsades de pointes. Drug Saf, 1999; 21 (suppl. 1): 5-10.
3. Zareba W, Moss AJ, le Cessie S. Risk of cardiac events in family members of patients with long QT syndrome. J Am Coll Cardiol, 1995; 26: 1685-1691.
4. Zareba W, Moss AJ, Schwartz PJ et al. Influence of the genotype on the clinical course of the long QT syndrome. N Engl J Med, 1998; 339: 960-965.
5. www.qtdrugs.org
6. National Association of Chain Drug Stores. 2000 Community Pharmacy Results. Alexandria, VA 2001.
7. Committee on Quality of Heath Care in America: Institute of Medicine. To err is human: building a safer health system. Washington, DC. National Academy Press 2000.
8. Lazarou J, Pomeranz B, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meat-analysis of prospective studies. JAMA, 1998; 279: 1200-1205.
9. Selzer A, Wray HW. Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias. Circulation, 1964; 30: 17-26.
10. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur Vaiss, 1966; 59: 263-272.
11. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J, 1986; 111: 1088-1093.
12. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsades de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol, 1983; 2: 806-817.
13. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA, 1993; 270: 2590-2597.
14. The CAST Investigators. Increased mortality due to encainide or flecainide in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med, 1989; 321: 406-412.
15. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA, 1993; 269: 1532-1536.
16. De Bruin ML, Langendijk PN, Koopmans RP, Wilde AA, Leufkens HG, Hoes AW. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol, 2007; 63: 216-223.
17. Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol 2000; 36: 1-12.
18. Napolitano C, Priori SG, Schwartz PJ et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA, 2005; 294: 2975-2980.
19. Antzelevitch Fadi AG, Yan GX, Antzelevitch C, Rosenbaum DS. Unique topographical distribution of M cells underlies reentrant mechanism of torsades de pointes in the long-QT syndrome. Circulation, 2002; 105: 1247-1253.
20. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol, 2002; 17: 43-51.
21. Antzelevitch C, Belardinelli L, Zygmunt AC et al. Electrophysiologic effects of ranolazine: A novel anti-anginal agent with antiarrhythmic properties. Circulation, 2004; 110: 904-910.
22. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell, 2001; 104: 569-580.
23. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell, 1995; 81: 299-307.
24. Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation. Psychiatr Q, 2003; 74: 291-306.
25. Viskin S, Rosovski U, Sands AJ et al. Inaccurate electrocardiographic interpretation of long QT: The majority of physicians cannot recognize a long QT when they see one. Heart Rhythm, 2005; 2: 569-574.
26. Zareba W. Dispersion of repolarization: time to move beyond QT dispersion. Ann Noninvasive Electrocardiol, 2000; 5: 373-381.
27. Bazett HC. An analysis of time relations of electrocardiograms. Heart, 1920; 7: 353-367.
28. Fridericia LS. Duration of systole in electrocardiogram. Acta Med Scandinav, 1920; 53: 469.
29. Sagie A. Larson MG. Goldberg RJ. Bengtson JR. Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol, 1992; 70: 797-801.
30. Hodges M, Salerno D, Erlien D. Bazett's QT correction reviewed: Evidence that alinear QT correction for heart rate is better. J Am Coll Cardiol, 1983; 1: 694.
31. Rautaharju PM, Zhou SH, Wong S et al. Sex differences in the evolution of electrocardiographic QT interval with age. Can J Cardiol, 1992; 8: 690-695.
32. Karjalainen J, Viitasalo M, Manttari M. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiogram of men and a simple method to adjust QT interval values. J Am Coll Cardiol, 1994; 23: 1547-1553.
33. Extramiana F, Maison-Blanche P, Haggui A, Badilini F, Beaufils P, Leenhardt A. Control of rapid heart rate changes for electrocardiographic analysis: implications for thorough QT studies. Clin Cardiol, 2006; 29: 534-539.
34. Moss AJ, Robinson J. Clinical features of the idiopathic long QT syndrome. Circulation, 1992; 85 (suppl. 1): I140-I144.
35. Fenichel RR, Malik M, Antzelevitch C et al. Drug - induced torsade de pointes and implications for drug development. J Cardiovasc Electrophysiol, 2004; 15: 475-495.
36. Moss AJ, Zareba W, Benhorin J et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation, 1995; 92: 2929-2934.
37. Liu T, Brown BS, Wu Y, Antzelevitch C, Kowey PR, Yan GX. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm, 2006; 3: 948-956.
38. Yamaguchi M, Shimizu M, Ino H et al. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (Lond), 2003; 105: 671-676.
39. Shimizu M, Ino H, Okeie K et al. T-peak to T-end interval may be a better predictor of high-risk patients with hypertrophic cardiomyopathy associated with a cardiac troponin I mutation than QT dispersion. Clin Cardiol, 2002; 25: 335-339.
40. Couderc JP, Zareba W, Moss AJ, Sarapa N, Morganroth J, Darpo B. Identification of sotalol-induced changes in repolarization with T wave area-based repolarization duration parameters. J Electrocardiol, 2003; (suppl. 36): 115-120.
41. Couderc JP, McNitt S, Xia J, Zareba W, Moss AJ. Repolarization morphology in adult LQT2 carriers with borderline prolonged QTc interval. Heart Rhythm, 2006; 3: 1460-1466.
42. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest, 2005; 115: 2025-2032.
43. Roden DM. Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophysiol, 2000; 11: 938-940.
44. Arking DE, Pfeufer A, Post W et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet, 2006; 38: 644-651.
45. Newton-Cheh C, Guo CY, Larson MG et al. Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study. Circulation, 2007; 116: 1128-1136.
46. Sesti F, Abbott GW, Wei J et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA, 2000; 97: 10613-10618.
47. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA, 2002; 287: 2273-2275.
48. Haverkamp W, Breithardt G, Camm AJ et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications: report on a policy conference of the European Society of Cardiology. Eur Heart J, 2000; 21: 1216-1231.
49. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA, 2002; 287: 2215-2220.
50. International Conference on Harmonisation. Guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Fed Regist, 2005; 70: 61134-61135.